Shuttle Pharmaceuticals (NASDAQ:SHPH) Trading Down 3.3% – Here’s What Happened

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH)’s stock price fell 3.3% on Wednesday . The company traded as low as $3.42 and last traded at $3.49. 24,148 shares traded hands during trading, a decline of 84% from the average daily volume of 146,551 shares. The stock had previously closed at $3.61.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Weiss Ratings cut shares of Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, August 21st. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Stock Performance

The firm’s 50 day simple moving average is $3.58 and its 200-day simple moving average is $6.24. The company has a market cap of $2.22 million, a price-to-earnings ratio of -0.07 and a beta of 0.21.

Insider Buying and Selling at Shuttle Pharmaceuticals

In other Shuttle Pharmaceuticals news, major shareholder Financial Lp Hrt purchased 25,836 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were purchased at an average cost of $3.44 per share, for a total transaction of $88,875.84. Following the completion of the transaction, the insider owned 71,842 shares of the company’s stock, valued at $247,136.48. The trade was a 56.16% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last quarter, insiders have bought 53,398 shares of company stock valued at $181,764 and have sold 38,133 shares valued at $132,128. Corporate insiders own 0.36% of the company’s stock.

Institutional Trading of Shuttle Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Connective Capital Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals in the third quarter valued at approximately $357,000. Ikarian Capital LLC purchased a new position in Shuttle Pharmaceuticals during the fourth quarter worth approximately $124,000. Boothbay Fund Management LLC purchased a new position in Shuttle Pharmaceuticals during the fourth quarter worth approximately $37,000. Finally, Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals during the fourth quarter worth $26,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .